Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Detlef Kozian
Detlef Kozian, Hattersheim DE
| Patent application number | Description | Published |
|---|---|---|
| 20100221714 | ANALYSIS AND USE OF PAR1 POLYMORPHISMS FOR EVALUATING THE RISK OF CARDIOVASCULAR DISEASE - The invention relates to polynucleotide sequences comprising genetic variations of the PAR1 gene at positions 3090 and/or 3329. The occurrence of these variants in humans correlates with increased occurrence of particular cardiovascular disorders. The invention furthermore relates to methods for detecting said genetic variations for the purpose of patient diagnosis. | 09-02-2010 |
| 20100221738 | METHOD OF DIAGNOSIS OF A PREDISPOSITION TO DEVELOP THROMBOTIC DISEASE AND ITS USES - The present invention refers to a method of diagnosis of a predisposition to develop thrombotic disease, to test systems and their use for the diagnosis of a predisposition to develop thrombotic disease, to a P | 09-02-2010 |
| 20110104704 | ASSOCIATION OF EDG5 POLYMORPHISM V286A WITH TYPE II DIABETES MELLITUS AND VENOUS THROMBOSIS/PULMONARY EMBOLISM AND THE USE THEREOF - The present invention relates to a method of identifying an increase in risk for type II Diabetes mellitus, venous thrombosis, or pulmonary embolism in a subject, wherein the presence of an amino acid exchange at position 286 from valine (Val) to alanine (Ala) in the EDG5 protein in a biological sample taken from the subject. | 05-05-2011 |
Detlef Kozian, Kelkheim DE
| Patent application number | Description | Published |
|---|---|---|
| 20090239237 | METHOD FOR THE IDENTIFICATION OF A RISK FOR A THROMBOGENIC DISORDER BY DETERMINING THE TAFl-lle347 POLYMORPHISM - The present invention is directed to a method identifying a risk for a thrombogenic disorder including, without limitation, atrial fibrillation, stroke, prolonged intermitted neurological deficit (PRIND), transitory ischemic attack (TIA), atherosclerotic cerebrovascular disease (CVD) and/or coronary heart disease, as well as to a method for selecting patients with a risk for a thrombogenic disorder, to a method for identifying a pharmaceutical for the therapy or prophylaxis of a thrombogenic disorder as well as to a method for producing a medicament and a diagnostic by employing the TAFI-Ile347 polymorphism. | 09-24-2009 |
| 20100311053 | USE OF CLEC1B FOR THE DETERMINATION OF CARDIOVASCULAR AND THROMBOTIC RISK - The use of the single nucleotide polymorphism (SNP) of the CLEC1B gene for the identification of cardiovascular and/or thrombotic disorders or of an increased risk for developing cardiovascular and/or thrombotic disorders in a biological sample taken from an individual to be examined; the use of CLEC1B for identifying substances active in preventing and/or treating cardiovascular and/or thrombotic disorders and methods for doing so. | 12-09-2010 |
Detlef Kozian, Kelkeim DE
| Patent application number | Description | Published |
|---|---|---|
| 20100062431 | USE OF ADAMTS4 GENE AND PROTEIN POLYMORPHISMS - The use of the single nucleotide polymorphism (SNP) of the ADAMTS4 gene for the identification of cardiovascular and peripheral vascular disorders or of an increased risk for developing cardiovascular and peripheral vascular disorders in a biological sample taken from an individual to be examined; the use of ADAMTS4 for identifying substances active in preventing and/or treating cardiovascular and peripheral vascular disorders and methods for doing so. | 03-11-2010 |
| 20110123515 | EGLN2 VARIANTS AND USE THEREOF IN PREVENTING OR TREATING THROMBOEMBOLIC DISORDERS AND CORONARY HEART DISEASES - The present invention refers to human EGLN2 variants having at position 58 of the amino acid sequence a serine or a leucine and their use in the prevention or treatment of thromboembolic or coronary heart diseases, in particular stroke, prolonged reversible ischemic neurological deficit (PRIND), transitoric ischemic attack (TIA), myocardial infarction and/or early myocardial infarction. | 05-26-2011 |
Detlef Kozian, Frankfurt Am Main DE
| Patent application number | Description | Published |
|---|---|---|
| 20080312098 | Use of a Gip Promoter Polymorphism - The use of the single nucleotide polymorphism (SNP) at position −(97) of the GIP gene for the identification of a cardiovascular disease or of an increased risk for developing a cardiovascular disease in a biological sample taken from an individual to be examined. | 12-18-2008 |
| 20090197774 | METHOD FOR DIAGNOSING THROMBOEMBOLIC DISORDERS AND CORONARY HEART DISEASE - The present invention refers to a method for the in vitro diagnosis of thromboembolic and/or coronary heart diseases, wherein the nucleotide at position 470 of a nucleic acid coding for the human EGLN2 protein or the amino acid at position 58 of the human EGLN2 protein of a sample of a person is determined. | 08-06-2009 |
| 20090220479 | EGLN2 VARIANTS AND USE THEREOF IN PREVENTING OR TREATING THROMBOEMBOLIC DISORDERS AND CORONARY HEART DISEASE - The present invention refers to human EGLN2 variants having at position 58 of the amino acid sequence a serine or a leucine and their use in the prevention or treatment of thromboembolic or coronary heart diseases, in particular stroke, prolonged reversible ischemic neurological deficit (PRIND), transitoric ischemic attack (TIA), myocardial infarction and/or early myocardial infarction. | 09-03-2009 |
| 20090239218 | METHOD FOR THE DIAGNOSIS AND TREATMENT OF CARDIOVASCULAR DISEASES - The present invention refers to a method for the in vitro or in vivo diagnosis of cardiovascular diseases, in particular high blood pressure, stenosis, vessel occlusion and/or other thrombotic events, wherein the nucleotide at position 950 of a nucleic acid coding for the human ARK2 protein or the amino acid at position 298 of the human ARK2 protein of a sample of a person is determined as well as to the use of ARK2 for the development and/or production of a medicament for treating a cardiovascular disease. | 09-24-2009 |